St. Jude, WHO tell us how their $200M initiative would fix global drug shortages for kids with cancer—and (maybe) adults January 28, 2022Vol.48 No.04By Matthew Bin Han Ong
Conversation with The Cancer Letter St. Jude’s James Downing: The solution for drug shortages isn’t regional—it has to be global January 28, 2022Vol.48 No.04By Matthew Bin Han Ong
Conversation with The Cancer Letter Carlos Rodriguez-Galindo: St. Jude’s new platform is designed to become global authority on disparities in drug access January 28, 2022Vol.48 No.04By Matthew Bin Han Ong
Guest Editorial Novel mentorship program tackles disparities in clinical research January 28, 2022Vol.48 No.04By Roy S. Herbst, Yu Shyr and Robert A. Winn
FreeIn the Archives Career milestones: Jedd Wolchok, Steven Nurkin, Camille Ragin January 28, 2022Vol.48 No.04
Conversation with The Cancer Letter Robert Stone: How City of Hope will go national through acquisition of Cancer Treatment Centers of America January 21, 2022Vol.48 No.03By Paul Goldberg
CPRIT scientists: We do not accept Texas’ harmful COVID policies, attack on women’s reproductive rights January 21, 2022Vol.48 No.03By Matthew Bin Han Ong
To combat IP theft, NIH strengthens disclosure requirements for grant recipients January 21, 2022Vol.48 No.03By Alice Tracey
FreeGuest Editorial Congress, Biden have an opportunity to invest in cancer research today for better treatments, cures tomorrow January 21, 2022Vol.48 No.03By David A. Tuveson
